Publicaciones (61) Publicaciones en las que ha participado algún/a investigador/a

2022

  1. A mi amigo Enrique Reig

    MPJ Multidisciplinary Pain Journal, Núm. 1

  2. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

    Therapeutic Advances in Medical Oncology, Vol. 14

  3. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  4. Anomalías congénitas y patología inflamatoria de la mama

    Obstetricia y ginecología (Elsevier), pp. 448-453

  5. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    CA Cancer Journal for Clinicians, Vol. 72, Núm. 2, pp. 165-182

  6. Association between sexual satisfaction and resilience in premenopausal women

    Revista de Obstetricia y Ginecologia de Venezuela, Vol. 82, Núm. 3, pp. 322-328

  7. Association of Age and Surgical Technique with the Quality of Life of Male Patients Treated for Abdominal Aorta Aneurysms: A Cross-Sectional Study

    International Journal of Environmental Research and Public Health, Vol. 19, Núm. 11

  8. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*

    British Journal of Dermatology, Vol. 187, Núm. 6, pp. 962-969

  9. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

    eBioMedicine, Vol. 75

  10. Diagnosis of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors

    JAMA Dermatology

  11. Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases

    Cancers, Vol. 14, Núm. 5

  12. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

    PharmacoEconomics, Vol. 40, Núm. 5, pp. 519-558

  13. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  14. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    Journal of the European Academy of Dermatology and Venereology, Vol. 36, Núm. 3, pp. 332-350

  15. Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?

    Cancers, Vol. 14, Núm. 7

  16. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

    Cancers, Vol. 14, Núm. 20

  17. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

  18. GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer

    Future Oncology, Vol. 18, Núm. 34, pp. 3801-3813

  19. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

    npj Breast Cancer, Vol. 8, Núm. 1

  20. Harmonizing PD-L1 testing in metastatic triple negative breast cancer

    Expert Opinion on Biological Therapy